Reuters logo
BRIEF-DBV Technologies says Viaskin Peanut study demonstrates good tolerance and safety of product
November 20, 2017 / 7:24 AM / 25 days ago

BRIEF-DBV Technologies says Viaskin Peanut study demonstrates good tolerance and safety of product

Nov 20 (Reuters) - DBV TECHNOLOGIES SA:

* SAYS STUDY DEMONSTRATES GOOD TOLERANCE AND SAFETY OF PRODUCT, COMPARABLE TO PREVIOUS STUDIES

* FIST PERIOD OF STUDY COMPARED SAFETY OF TREATMENT WITH VIASKIN PEANUT 250 ΜG TO PLACEBO FOR 6 MTHS

* RESULTS WILL SERVE AS A BASIS FOR PLANNED DISCUSSIONS WITH REGULATORY AUTHORITIES

* SOME SERIOUS ADVERSE EVENTS WERE OBSERVED IN THE TRIAL

* PATIENTS WHO COMPLETED FIRST PART OF STUDY WILL RECEIVE ACTIVE TREATMENT FOR 36 MTHS See also :

‍​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below